RECURSION PHARMACEUTICALS, INC.
RXRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RXRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RXRX
Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging an AI-enabled platform to discover and develop therapies for a range of diseases, with no approved products and a history of operating losses.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 9 clinical trials for RECURSION PHARMACEUTICALS, INC..
Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging an AI-enabled platform to discover and develop therapies for a range of diseases, with no approved products and a history of operating losses.
- Recursion Pharmaceuticals is a clinical-stage biotech company using an AI-driven platform for drug discovery [sec].
- As of June 30, 2026, the company reported cash & equivalents of $556.8M, total revenue of $7.7M, and a net loss of -$131.0M [sec].
- The company has no approved products and has not generated any revenue from product sales [sec].
- Recursion has a collaboration with Roche, receiving a $150.0M upfront payment in January 2022 [sec].
- As of March 31, 2023, the accumulated deficit was $704.9M [sec].
What works
- The company has a strong cash position of $556.8M as of June 30, 2026, providing a runway for operations [sec].
- Recursion has established a significant collaboration with Roche, including a $150.0M upfront payment, validating its platform [sec].
- The AI-enabled platform allows for efficient drug discovery across multiple therapeutic areas, potentially reducing development time and costs [sec].
What to weigh
- The company has a history of operating losses, with a net loss of -$131.0M for the six months ended June 30, 2026, and an accumulated deficit of $704.9M as of March 31, 2023 [sec].
- Recursion has no approved products and has not generated any revenue from product sales, relying on external financing for operations [sec].
- The company faces significant risks common to biotech firms, including uncertainty of clinical trial outcomes and the need for additional funding [sec].
From the filings
Quoted directly from source documents.
The company has no approved products and has not generated product sales revenue.
“We do not have any products approved for commercial sale and have not generated any revenues from product sales.”
SEC filings · August 9, 2022
Recursion has a collaboration with Roche with a $150.0M upfront payment.
“we announced a collaboration with Roche and received an upfront payment of $150.0 million in January 2022”
SEC filings · August 9, 2022
The company has incurred significant operating losses and has an accumulated deficit.
“Since inception, we have incurred significant operating losses. Our net losses were $65.3 million and $56.0 million during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, our accumulated deficit was $704.9 million.”
SEC filings · May 8, 2023
The company expects to need additional financing for operations and commercialization.
“We anticipate that we will need to raise additional financing in the future to fund our operations, including the potential commercialization of any approved product candidates.”
SEC filings · May 8, 2023
Risks & what to watch (4)›
Key risks
- No approved products — The company has no products approved for commercial sale and has not generated any product revenue [sec].
- History of operating losses — Recursion has incurred significant operating losses, with a net loss of -$131.0M for the six months ended June 30, 2026 [sec].
- Need for additional funding — The company anticipates needing to raise additional financing to fund operations and potential commercialization [sec].
- Clinical trial uncertainty — The company is subject to risks common in biotech, including uncertainty of clinical trial outcomes [sec].
What to watch
- Progress of clinical trials for drug candidates and any regulatory filings [sec].
- Updates on the collaboration with Roche and potential new partnerships [sec].
- Cash runway and any future financing events, given the need for additional funding [sec].
- Any announcements regarding product approvals or commercialization milestones [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run RECURSION PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RECURSION PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.2 months
D/E 0.33 · 0% dilution
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
0 buys · 17 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
337
Total value held
$1.01B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 44,488,774 | $136.6M |
| blackrock, inc. | 43,192,306 | $132.6M |
| ark investment management llc | 40,212,769 | $123.5M |
| state street corp | 28,490,638 | $87.5M |
| vanguard portfolio management llc | 22,759,100 | $69.9M |
| softbank group corp. | 13,636,515 | $41.9M |
| geode capital management, llc | 12,275,084 | $37.7M |
| susquehanna international group, llp | 8,385,877 | $25.7M |
| goldman sachs group inc | 6,065,661 | $18.6M |
| data collective iv gp, llc | 5,941,120 | $18.2M |
Showing top 10 of 337 institutional holders of RECURSION PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 34.9%
- Days to cover
- 14.0
- Shares short
- 174,397,876
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RXRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for RECURSION PHARMACEUTICALS, INC.?
Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging an AI-enabled platform to discover and develop therapies for a range of diseases, with no approved products and a history of operating losses.
What is RECURSION PHARMACEUTICALS, INC.'s lead drug candidate?
RECURSION PHARMACEUTICALS, INC.'s most advanced tracked candidate is REC-1245 (Phase 1/Phase 2) for Unresectable.
Who is the CEO of RECURSION PHARMACEUTICALS, INC.?
Dr. Najat Khan Ph.D. is the chief executive officer of RECURSION PHARMACEUTICALS, INC. (RXRX).
Where is RECURSION PHARMACEUTICALS, INC. headquartered?
RECURSION PHARMACEUTICALS, INC. (RXRX) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does RECURSION PHARMACEUTICALS, INC. focus on?
RECURSION PHARMACEUTICALS, INC. develops therapies across Oncology, Rare Disease, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.